Appeals court affirmed that SM-102 does not infringe Alnylam’s mRNA patents. The decision supports Moderna’s use of SM-102 in its Spikevax COVID-19 vaccine. Live on Wednesday June 18: 3 Summer ...

Guided by the theme of “Accepting Challenges to Improve the Health of Humanity,” Alnylam continues to take meaningful steps across each of its six corporate responsibility pillars. This year ...

An Alnylam spokesperson said the company was evaluating its options and may appeal. A BioNTech spokesperson said the filing "confirms Pfizer's and BioNTech's position that we do not infringe any ...

Twenty-two years in and Alnylam Pharmaceuticals is still not raking in any profit. But that’s a testament to the company’s R&D focus, because it takes more than one or two successful drugs to ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based ...

Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR ...

Alnylam Pharmaceuticals (ALNY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

Alnylam concedes its inability to secure a judgment against Moderna’s products after the court’s claim construction. Moderna’s counterclaims and affirmative defenses were dismissed without ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on ...

Getty Images Alnylam Pharmaceuticals announced a Phase-3 study of its treatment for a rare heart condition showed a significant reduction in deaths and recurrent cardiovascular events. The ...